Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

[Revascularization in patients with type 2 diabetes and coronary artery disease: BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) Study Group].

Störk S, Ertl G, Nitschmann S.

Internist (Berl). 2010 May;51(5):674-6. doi: 10.1007/s00108-010-2593-6. German. No abstract available.

PMID:
20352177
2.

A randomized trial of therapies for type 2 diabetes and coronary artery disease.

BARI 2D Study Group., Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, Orchard TJ, Chaitman BR, Genuth SM, Goldberg SH, Hlatky MA, Jones TL, Molitch ME, Nesto RW, Sako EY, Sobel BE.

N Engl J Med. 2009 Jun 11;360(24):2503-15. doi: 10.1056/NEJMoa0805796. Epub 2009 Jun 7.

3.

Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.

Sobel BE, Hardison RM, Genuth S, Brooks MM, McBane RD 3rd, Schneider DJ, Pratley RE, Huber K, Wolk R, Krishnaswami A, Frye RL; BARI 2D Investigators..

Circulation. 2011 Aug 9;124(6):695-703. doi: 10.1161/CIRCULATIONAHA.110.014860. Epub 2011 Jul 18.

4.

Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.

Bach RG, Brooks MM, Lombardero M, Genuth S, Donner TW, Garber A, Kennedy L, Monrad ES, Pop-Busui R, Kelsey SF, Frye RL; BARI 2D Investigators..

Circulation. 2013 Aug 20;128(8):785-94. doi: 10.1161/CIRCULATIONAHA.112.000678. Epub 2013 Jul 15.

5.

Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort.

Pop-Busui R, Lu J, Lopes N, Jones TL; BARI 2D Investigators..

J Peripher Nerv Syst. 2009 Mar;14(1):1-13. doi: 10.1111/j.1529-8027.2009.00200.x.

6.

The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction.

Chaitman BR, Hardison RM, Adler D, Gebhart S, Grogan M, Ocampo S, Sopko G, Ramires JA, Schneider D, Frye RL; Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Study Group..

Circulation. 2009 Dec 22;120(25):2529-40. doi: 10.1161/CIRCULATIONAHA.109.913111. Epub 2009 Nov 17. Erratum in: Circulation. 2010 Mar 30;121(12):e254.

7.

Response to letter regarding article, "rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial".

Bach RG, Brooks MM, Lombardero M, Genuth S, Donner TW, Garber A, Kennedy L, Monrad ES, Pop-Busui R, Kelsey SF, Frye RL; BARI 2D Investigators..

Circulation. 2014 Apr 22;129(16):e460-1. doi: 10.1161/CIRCULATIONAHA.113.008033. No abstract available.

8.

Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.

Bypass Angioplasty Revascularization Investigation 2 Diabetes Study Group..

Am Heart J. 2008 Sep;156(3):528-536, 536.e1-5. doi: 10.1016/j.ahj.2008.05.015. Epub 2008 Jul 31.

9.

The BARI 2D study: a randomised trial of therapies for type 2 diabetes and coronary artery disease.

Rutter MK, Nesto RW.

Diab Vasc Dis Res. 2010 Jan;7(1):69-72. doi: 10.1177/1479164109354145.

PMID:
20368235
10.

Relation of severe coronary artery narrowing to insulin or thiazolidinedione use in patients with type 2 diabetes mellitus (from the Bypass Angioplasty Revascularization Investigation 2 Diabetes Study).

Pop-Busui R, Lombardero M, Lavis V, Forker A, Green J, Korytkowski M, Sobel BE, Jones TL; BARI 2D Study Group..

Am J Cardiol. 2009 Jul 1;104(1):52-8. doi: 10.1016/j.amjcard.2009.02.046. Epub 2009 May 13.

11.

Case-control study of second-line therapies for type 2 diabetes in combination with metformin and the comparative risks of myocardial infarction and stroke.

Floyd JS, Wiggins KL, Sitlani CM, Flory JH, Dublin S, Smith NL, Heckbert SR, Psaty BM.

Diabetes Obes Metab. 2015 Dec;17(12):1194-7. doi: 10.1111/dom.12537. Epub 2015 Oct 5.

12.

The effect of age on clinical outcomes and health status BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes).

Chung SC, Hlatky MA, Faxon D, Ramanathan K, Adler D, Mooradian A, Rihal C, Stone RA, Bromberger JT, Kelsey SF, Brooks MM; BARI 2D Study Group..

J Am Coll Cardiol. 2011 Aug 16;58(8):810-9. doi: 10.1016/j.jacc.2011.05.020.

13.
14.

[Should the occurrence of a first coronary event change the management of diabetes?].

Timsit J, Dubois-Laforgue D.

Arch Mal Coeur Vaiss. 2000 Dec;93 Spec No 4:39-44. Review. French.

PMID:
11296461
15.

Sex differences in presentation and outcome among patients with type 2 diabetes and coronary artery disease treated with contemporary medical therapy with or without prompt revascularization: a report from the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation 2 Diabetes).

Tamis-Holland JE, Lu J, Korytkowski M, Magee M, Rogers WJ, Lopes N, Mighton L, Jacobs AK; BARI 2D Study Group..

J Am Coll Cardiol. 2013 Apr 30;61(17):1767-76. doi: 10.1016/j.jacc.2013.01.062. Epub 2013 Feb 28.

16.

10-year follow-up of intensive glucose control in type 2 diabetes.

Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA.

N Engl J Med. 2008 Oct 9;359(15):1577-89. doi: 10.1056/NEJMoa0806470. Epub 2008 Sep 10.

18.

Summaries for patients. How do older diabetes drugs compare in their effects on heart and blood vessel disease?

[No authors listed]

Ann Intern Med. 2012 Nov 6;157(9):I-28. doi: 10.7326/0003-4819-157-9-201211060-00001. No abstract available.

PMID:
23128878
19.

Health status after treatment for coronary artery disease and type 2 diabetes mellitus in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial.

Brooks MM, Chung SC, Helmy T, Hillegass WB, Escobedo J, Melsop KA, Massaro EM, McBane RD, Hyde P, Hlatky MA; Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Study Group..

Circulation. 2010 Oct 26;122(17):1690-9. doi: 10.1161/CIRCULATIONAHA.109.912642. Epub 2010 Oct 11.

20.

Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.

Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G.

Diabetes Care. 2006 Mar;29(3):554-9.

PMID:
16505505

Supplemental Content

Support Center